Book contents
- Frontmatter
- Contents
- Editor, Associate Editors, Artistic Consultant, and Contributors
- Preface
- PART I CONTEXT
- PART II ENDOTHELIAL CELL AS INPUT-OUTPUT DEVICE
- PART III VASCULAR BED/ORGAN STRUCTURE AND FUNCTION IN HEALTH AND DISEASE
- PART IV DIAGNOSIS AND TREATMENT
- 172 Introductory Essay: Diagnosis and Treatment
- 173 Circulating Markers of Endothelial Function
- 174 Blood Endothelial Cells
- 175 Endothelial Microparticles: Biology, Function, Assay and Clinical Application
- 176 Molecular Magnetic Resonance Imaging
- 177 Real-Time Imaging of the Endothelium
- 178 Diagnosing Endothelial Cell Dysfunction
- 179 Statins
- 180 Steroid Hormones
- 181 Organic Nitrates: Exogenous Nitric Oxide Administration and Its Influence on the Vascular Endothelium
- 182 Therapeutic Approaches to Altering Hemodynamic Forces
- 183 Stent- and Nonstent-Based Cell Therapy for Vascular Disease
- 184 Building Blood Vessels
- 185 Gene Transfer and Expression in the Vascular Endothelium
- 186 Drug Targeting to Endothelium
- PART V CHALLENGES AND OPPORTUNITIES
- Index
- Plate section
181 - Organic Nitrates: Exogenous Nitric Oxide Administration and Its Influence on the Vascular Endothelium
from PART IV - DIAGNOSIS AND TREATMENT
Published online by Cambridge University Press: 04 May 2010
- Frontmatter
- Contents
- Editor, Associate Editors, Artistic Consultant, and Contributors
- Preface
- PART I CONTEXT
- PART II ENDOTHELIAL CELL AS INPUT-OUTPUT DEVICE
- PART III VASCULAR BED/ORGAN STRUCTURE AND FUNCTION IN HEALTH AND DISEASE
- PART IV DIAGNOSIS AND TREATMENT
- 172 Introductory Essay: Diagnosis and Treatment
- 173 Circulating Markers of Endothelial Function
- 174 Blood Endothelial Cells
- 175 Endothelial Microparticles: Biology, Function, Assay and Clinical Application
- 176 Molecular Magnetic Resonance Imaging
- 177 Real-Time Imaging of the Endothelium
- 178 Diagnosing Endothelial Cell Dysfunction
- 179 Statins
- 180 Steroid Hormones
- 181 Organic Nitrates: Exogenous Nitric Oxide Administration and Its Influence on the Vascular Endothelium
- 182 Therapeutic Approaches to Altering Hemodynamic Forces
- 183 Stent- and Nonstent-Based Cell Therapy for Vascular Disease
- 184 Building Blood Vessels
- 185 Gene Transfer and Expression in the Vascular Endothelium
- 186 Drug Targeting to Endothelium
- PART V CHALLENGES AND OPPORTUNITIES
- Index
- Plate section
Summary
Nitroglycerin (GTN) and other nitrates have been used in cardiovascular medicine for more than 120 years. GTN was first synthesized in 1847 by an Italian, Ascanio Sobrero, who described a “violent headache” upon self-administration of a “minute quantity” of the drug (1). Because of this side effect, investigation of possible pharmacological applications of GTN was limited for several years, until the reports of Brunton and Murrell, who employed nitrates in the treatment of angina (2,3). Although sublingual GTN has been commonly used for more than a century to treat acute attacks of angina, the development of organic nitrates with sustained activity was limited by their poor oral bioavailability. Eventually, this difficulty was overcome and long-acting formulations of GTN and other long-acting organic nitrates, including isosorbide dinitrate, isosorbide-5-mononitrate, and pentaerythritol tetranitrate, have been developed and marketed. More details on the pharmacologic characteristics, formulations, and indications of different nitrates have been reviewed recently (4).
BIOTRANSFORMATION AND HEMODYNAMIC EFFECTS
Organic nitrates are prodrugs that release their active principle, nitric oxide (NO) or a NO-containing compound, via an intracellular enzyme-dependent denitrification (5) (Figure 181.1). The exact determination of the enzyme system involved in this bioconversion has remained elusive, despite extensive investigation. Multiple enzymatic candidates have been identified, including cytochrome P450, endothelial NO synthase, and glutathione transferase (6–10). There has been intense interest in identifying the denitrification pathway because it was felt that the development of abnormalities in this process might explain the loss of nitrate effects during sustained therapy, a phenomenon termed nitrate tolerance (discussed later). Spontaneous thiol-dependent denitrification of GTN also has been proposed as the mechanism of GTN biotransformation.
- Type
- Chapter
- Information
- Endothelial Biomedicine , pp. 1682 - 1689Publisher: Cambridge University PressPrint publication year: 2007